Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Ingredients

BASF buys omega-3 maker Equateq citing pharma potential

By Gareth Macdonald , 09-May-2012
Last updated on 09-May-2012 at 13:24 GMT

BASF has bought omega-3 fatty acid maker Equateq, citing its pharmaceutical and dietary supplements businesses as key beneficiaries.

Equateq operates a facility on the Isle of Lewis, Scotland and produces omega-3 fatty acids using ‘unique’ technology that enables ‘exceptional purity levels’ according to BASF spokesman Andres-Christian Orthofer.

Equateq is the global leader in the production of highly concentrated omega-3 fatty acids, in particular for pharmaceutical grades of EPA and DHA with single-lipid concentrations of up to 99% purity” Orthofer told

He went on to say that Equateq's proprietary chromatographic separation methods allow flexible blending and formulation of omega-3 fatty acids at exceptional purity levels, which he predicted would provide BASF with a significant advantage in the market.

The capabilities of Equateq’s technologies will allow us to react to changing market demands and to offer bespoke omega-3 fatty acid concentrates with exceptional purity according to customer needs.”

Financial terms of the deal have not been disclosed. However, BASF did confirm that Equateq’s 47-strong workforce has joined its nutrition and health division.

Growing market

News of the acquisition follows a few months after BASF’s plant science unit teamed up with Cargill to create a new source of omega-3 fatty acid derived from GM canola oil and suggests the German firm sees potential for the ingredient in a number of markets.

This idea was further supported by Orthofer, who told that: “Growing consumer awareness of the health benefits of omega-3 is fueling double-digit growth for omega-3 products in the years to come. Omega-3 fatty acids have scientifically proven health benefits.”

To date Equateq has only publicly announced its involvement in one candidate pharmaceutical product – Amarin’s triglyceride lowering drug AMR101 (icosapent ethyl) – which finally received a US patent in March after a number of unexpected delays .

Comments that followed issuance of the patent also lend further support to BASF’s belief in the pharmaceutical omega-3 fatty acid market. Citi Investment Research analyst John Boris said that – if approved - drug could overtake GSK’s Lovaza and Abbott Lab’s Tricor and Trilipix and generate revenues of $1.5bn a year by 2020 .

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Related products

Key Industry Events


Access all events listing

Our events, Events from partners...